Is MedAvail a Winner in the Healthtech Industry? Shares of MedAvail (MDVL) have more than doubled in the past month. Let's see if this stock has more room to run.

By Aditya Raghunath

This story originally appeared on StockNews - StockNews

Shares of MedAvail (MDVL) have more than doubled in the past month. Let's see if this stock has more room to run.

Companies part of the digital health industry gained significant momentum in 2020 as the COVID-19 pandemic acted as a massive tailwind. Several countries imposed lockdowns and travel came to a standstill. As clinics were closed, the demand for digital health solutions accelerated quickly.

According to a report from Grand View Research, the global telehealth market is forecast to reach $787.4 billion, indicating annual growth rates of 36.5% in the forecast period. A rapidly expanding addressable market allows companies such as MedAvail (MDVL) to grow revenue at a robust pace over a period of time.

The evolution of smartphones and strong internet connectivity has made telehealth products and services accessible at a reasonable cost, driving adoption rates higher. Let's see if MedAvail should be part of your portfolio given the above-mentioned factors.

An overview of MedAvail

Valued at a market cap of $161 million, MedAvail is a tech-enabled retail pharmacy company. It develops and commercializes self-service pharmacy, mobile apps, kiosks as well as drive-thru solutions in the U.S. and Canada.

MedAvail has two primary business segments which are Retail Pharmacy Services and Pharmacy Technology. Its MedCenter enables on-site pharmacy in medical clinics, employer sites, and retail store locations. It also establishes an audio-visual connection to a pharmacist enabling the dispensing of prescription drugs to the patient on a real-time basis. Additionally, MedAvail owns and operates SpotRx which is a retail pharmacy platform.

The company has managed to increase sales from just $3.7 million in 2019 to $22.12 million in 2021. However, its operating loss widened from $20.7 million to $43.5 million in this period.

In Q4 of 2021, MedAvail reported revenue of $6.95 million, compared to $3 million in the year-ago period. However, its cost of sales also increased by 128% to $7.64 million.

What next for MedAvail stock investors?

Analysts tracking the stock expect MedAvail to increase sales by 86.8% to $41.33 million in 2022 and by 65.8% to $68.5 million in 2023. Comparatively, its adjusted loss per share might narrow from $1.34 in 2021 to $0.54 in 2023.

We can see that MedAvail stock is valued at a forward price to sales multiple of 4x which is quite reasonable given its growth rates. However, its less than impressive gross margins indicate, the company will have to grow revenue at a fast clip to turn profitable.

MedAvail ended 2021 with $19.7 million in cash and $12.25 million in debt which means it will have to raise equity capital and offset cash burn rates.

Earlier this month, MedAvail announced the closing of a private placement amounting to $40 million. It offered 37.6 million shares of common stock at an offer price of $1.0625 per share. The proceeds will be used for general corporate purposes as well as to fund strategic initiatives.

The Foolish takeaway

While there are several drivers positively impacting MedAvail stock, it remains a high-risk bet due to its small size and consistent losses. However, it might be a good acquisition target for some leading telehealth players.

I believe there are far better players in the telehealth industry, such as Teladoc (TDOC) and WELL Health Technologies (WHTCF), that should be considered instead of MedAvail right now.

MDVL shares fell $0.11 (-6.32%) in premarket trading Wednesday. Year-to-date, MDVL has gained 16.43%, versus a -7.41% rise in the benchmark S&P 500 index during the same period.

About the Author: Aditya Raghunath

Aditya Raghunath is a financial journalist who writes about business, public equities, and personal finance. His work has been published on several digital platforms in the U.S. and Canada, including The Motley Fool, Finscreener, and Market Realist.


The post Is MedAvail a Winner in the Healthtech Industry? appeared first on

Wavy Line

Editor's Pick

A Father Decided to Change When He Was in Prison on His Son's Birthday. Now His Nonprofit Helps Formerly Incarcerated Applicants Land 6-Figure Jobs.
A Teen Turned His Roblox Side Hustle Into a Multimillion-Dollar Company — Now He's Working With Karlie Kloss and Elton John
3 Mundane Tasks You Should Automate to Save Your Brain for the Big Stuff
The Next Time Someone Intimidates You, Here's What You Should Do
5 Ways to Manage Your Mental Health and Regulate Your Nervous System for Sustainable Success

Related Topics

Business News

'Do You Hate Me?': High School Teacher Shares Wild Emails He Receives From Students

Jordan Baechler teaches high school students in Ontario, Canada.

Growing a Business

How to Build a Thriving Community That Will Skyrocket Your Business

Build a strong community, and transform your business with these proven strategies.

Growing a Business

How Experiential Dining Offers Unforgettable Customer Experiences

With over 660,000 restaurants in the US alone, restaurant-goers have plenty of options to choose from. But what sets a restaurant apart from the rest?

Business News

'I Am Just Floored': Woman Discovers She Won $1 Million Lottery Prize While Checking Her Email at Work

Initially, she thought the email was a scam, but went to lottery headquarters and walked away with a six-figure check after taxes.


How to Overcome Imposter Syndrome as a Young Entrepreneur

How to recognize, cope with and overcome the feelings of self-doubt and inadequacy that plague many aspiring business owners.